Hutchison China MediTech Limited ("Chi-Med") is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.

Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is listed on the London Stock Exchange’s AIM market (AIM: HCM). It is majority owned by CK Hutchison Holdings Limited (SEHK: 0001), a leading international conglomerate committed to innovation and technology with over a quarter of a million employees in more than 50 countries and annual sales of over US$50 billion.

http://www.chi-med.com/eng/global/home.php

Global Phase III UC trial initiated with HPML-004

RNS


RNS Number : 0816D

Hutchison China Meditech Limited

24 April 2013




















Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)





Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004



London: Wednesday, 24 April 2013:Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has been enrolled and has begun treatment in the first global Phase III study of HMPL-004, NATRUL-3, in patients with mild-to-moderate ulcerative colitis ("UC").



HMPL-004 is a proprietary, novel, botanical oral drug in late stage development for the treatment of inflammatory bowel disease ("IBD"). It has undergone multiple clinical trials in North America, Europe and Asia, which showed efficacy in the induction of clinical response, remission, and mucosal healing; as well as a clean safety profile.



The Phase III registration trial programme to be named NATRUL is designed to evaluate the efficacy and safety of HMPL-004 in patients with mild-to-moderate UC. It consists of three separate randomised double-blind, multi-centre, placebo-controlled Phase III studies of HMPL-004.




NATRUL-3:

The primary endpoint of this study is to evaluate 8-week treatments of 1,800 mg/day and 2,400 mg/day dosages of HMPL-004 compared with placebo in patients with active UC who have an inadequate response to their current treatment with Mesalamine. Secondary endpoints of this study include clinical response and mucosal healing. The NATRUL-3 study is expected to take approximately 24 months to complete.


NATRUL-4:

This study is designed to evaluate HMPL-004 as a 52-week maintenance therapy. Subjects who have completed NATRUL-3 will be eligible to enter NATRUL-4 directly.


NATRUL-5:

This study is a second UC induction study to fulfil regulatory requirements.


A separate Crohn's disease programme will be triggered by satisfactory NATRUL-3 clinical data analysis. All HMPL-004 studies beyond NATRUL-3 will be announced separately upon treatment of their first patient.

The current standard of care for IBD starts with 5-aminosalicyclic acids (5-ASAs) which can induce and maintain clinical response and remission in an average of approximately 50% of IBD patients. For the 5-ASA non-responding patients with moderate-to-severe active diseases, various forms of corticosteroids and immunosuppressant drugs and anti-TNF agents such as biologics are prescribed. These agents, though effective, are associated with many side effects, sometimes serious, and are not often suitable for prolonged usage. There remain clear unmet medical needs for novel agents which can induce and maintain remission among 5-ASA non-responding or intolerant patients, and the need for safer agents without the side effects of corticosteroids and immune suppressors.

Dr. William Sandborn, Professor of Clinical Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System, said: "At the moment there are limited alternatives available for UC patients with mild to moderate disease who are seeking a safe and effective therapy. As a natural oral product with promising efficacy and an excellent safety profile, I expect patients and physicians alike to be enthusiastic at its potential if this trial is successful."

Christian Hogg, Chi-Med CEO said: "This is the first of what we expect to be many landmark events that will be achieved by our joint venture, Nutrition Science Partners, as it begins to invest in developing truly innovative and scientifically validated botanical based solutions for personalised healthcare. We are very pleased to start this global registration trial to help address IBD, a disease that is estimated to affect approximately 1.4 million in the US alone."



Ends

Hutchison China Medi: UBS ups target price from 520p to 590p keeping its buy recommendation.

A buy in this weeks IC - The company's deal with Nestle will allow it to progress its main HPML-004 gastro-intestinal product into phase iii trials. That Huchinson can get to this point is no mean achievement as a phase iii trial for such a product might involve up to 3000 patients and cost tens of millions. This puts Huchinson in a different league when it comes to biotech companies in the UK, with the aim company the most significant player outside of the big four pharma giants of AstraZeneca, GlaxoSmithKline, Shire and BTG. It has an enormous and rapidly developing market on its doorstep.

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during today's trading session when it reached 560.00. Over this period, the share price is up 25.14%.

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during today's trading session when it reached 599.50. Over this period, the share price is up 29.94%.

Financial calendar


Closure of Register of Members 09 May 2013 to 10 May 2013

Annual General Meeting 10 May 2013

As of May 03, 2013, the consensus forecast amongst 3 polled investment analysts covering Hutchison China MediTech Limited advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 22, 2012. The previous consensus forecast advised investors to purchase equity in Hutchison China MediTech Limited.

Trading statement due Friday 10 May.

Notice of Results

RNS


RNS Number : 5845H

Hutchison China Meditech Limited

24 June 2013














Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Notice of Announcement of 2013 Interim Results





London: Monday, 24 June 2013: Chi-Med will be announcing its interim results for the six months ended 30 June 2013 on Tuesday, 30 July 2013. An analyst presentation will be held at 9:00am on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY.







Ends

Volitinib Phase I triggers US$5 million milestone

RNS


RNS Number : 6906H

Hutchison China Meditech Limited

25 June 2013






Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)

Initiation of Volitinib China Phase I study triggers US$5 million milestone payment;
Australia Phase I study to report in late 2013





London: Tuesday, 25 June 2013: Chi-Med today announces that Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, has initiated the Phase I clinical trial of Volitinib (HMPL-504) in China, which entitles HMP to receive a cash milestone payment of US$5 million pursuant to the global licensing, co-development and commercialisation agreement entered into between AstraZeneca PLC and HMP in December 2011.



The primary objectives of the Phase I study of Volitinib in China are to evaluate its safety and tolerability in patients in China with advanced cancer and to determine its maximum tolerated dose. The study will also evaluate Volitinib's preliminary efficacy against various tumours, including lung cancer and gastric cancer, both being major unmet medical needs in China. The c-Met gene amplification status and protein expression levels will be evaluated to help inform subsequent patient selection strategies.



In February 2012, HMP commenced the first-in-human Phase I clinical trial of Volitinib in Australia which has progressed well through multiple dose levels and continues as a study of safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy against multiple tumour types, particularly among Caucasian patients. Results of the Phase I trial in Australia are expected in late 2013. Furthermore, the Phase I trial in Australia provides a guide for the selection of the recommended starting dose for the Phase I study in China.



Volitinib is a potent ATP-competitive c-Met inhibitor with high selectivity over a 274 kinase panel. Pre-clinical studies of Volitinib have demonstrated tumour growth inhibitory activity in a series of human tumour xenografts, especially for those tumours with c-Met gene amplification or c-Met over-expression.




Ends

Global Phase III HPML-004 maintenance study starts

RNS


RNS Number : 4497J

Hutchison China Meditech Limited

17 July 2013












Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)





Nutrition Science Partners announces initiation of NATRUL-4,
the maintenance study of the global Phase III trial for HMPL-004





London: Wednesday, 17 July 2013: Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has begun treatment in the second global Phase III study of HMPL-004, NATRUL-4, for mild-to-moderate ulcerative colitis ("UC").



HMPL-004 is a proprietary, novel, botanical oral drug in late stage development for the treatment of inflammatory bowel disease ("IBD"). It has undergone multiple clinical trials in North America, Europe and Asia, which showed efficacy in the induction of clinical response, remission, and mucosal healing; as well as a clean safety profile.



NATRUL-4 is a global Phase III study designed to evaluate the efficacy and safety of HMPL-004 as maintenance therapy in adults with mild-to-moderate active UC. It consists of an open-label induction treatment phase and a randomised, double-blind, placebo controlled maintenance therapy phase. Patients entering the maintenance phase of this study are those who have achieved clinical remission or response during their participation in either a randomised double-blind, placebo controlled HMPL-004 induction study (NATRUL-3 or NATRUL-5), or the 8-week open-label HMPL-004 induction treatment phase of the study. Eligible patients (clinical remitters and responders) will be randomised to receive either HMPL-004 at 1,800 mg/day or placebo for 52 weeks as maintenance therapy.



The primary endpoint of this study is the proportion of patients who are in remission after 52 weeks of maintenance treatment, following either successful induction therapy to achieve remission, or successful induction therapy to achieve response.



Key secondary endpoints of this study include the proportion of patients that have maintained remission only after induction into remission; the proportion of patients that are in response after induction into either remission or response; and the proportion of patients that have maintained response following induction into response.





Ends

Interim Results

RNS


RNS Number : 4081K

Hutchison China Meditech Limited

30 July 2013










Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Interim Results for the Six Months Ended 30 June 2013



Continued strong growth, especially in Drug R&D and China Healthcare. Outlook positive.





London: Tuesday, 30 July 2013: Chi-Med, the China-based healthcare and consumer products group, today announces its unaudited financial results for the six months ended 30 June 2013.



Group results are reported for the first time under the new International Financial Reporting Standard, IFRS 11 "Joint Arrangements" ("IFRS11"), which establishes the equity accounting principle for the reporting of joint ventures ("JVs") and means that the income statements and statements of financial position of JVs will no longer be proportionately consolidated. However, total revenues of the JVs will continue to be disclosed under the divisional summaries below.



Results are reported in US dollar currency unless otherwise stated.





Group Results

· Revenue, under IFRS11, on continuing operations up 74% to $17.6 million (H1 2012: $10.1m).

· Net profit attributable to Chi-Med equity holdersgrew 598% to$3.3 million (H1 2012: -$0.7m).

· Solid cash position: cash and cash equivalents at the Chi-Med Group level of $43.8 million (31 December 2012: $30.8m) in addition, and not included at the Group level, cash and cash equivalents held at the JV level totalled $101.4 million (31 December 2012: $62.4m).



China Healthcare Division

· Sales of subsidiaries and JVs up 22% to $227.5 million (H1 2012: $187.0m).

· Net profit attributable to Chi-Med equity holders up 18% to $14.4 million (H1 2012: $12.3m).

· Continued substantial growth in prescription drug and distribution businesses; over-the-counter ("OTC") drug business surge due to H7N9 outbreak in China, raw material prices however remain high.

· Value of land holdings expected to more than cover the cost of planned relocation and expansion of production facilities.

· Cash and cash equivalents held in our China Healthcare Division JVs totalled $75.2 million (31 December 2012: $62.4m).



Drug R&D Division

· Revenue up 265% to $10.5 million (H1 2012: $2.9m) due to a development milestone from AstraZeneca Plc ("AstraZeneca") and service income from Nutrition Science Partners Limited ("NSP") and Janssen Pharmaceuticals Inc. part of the Johnson & Johnson group of companies ("J&J").

· Net loss attributable to Chi-Med equity holders up 8% to $4.8 million (H1 2012: -$4.5m) due to start of NSP investment in HMPL-004 Phase III trials.

· Aggregate cash and equityinjections and contractual obligations from partners into Drug R&D Division subsidiaries and JVs during the period totalled $38.1 million (H1 2012: $0.6 m).

· Seven clinical trials accelerating rapidly and building value. Six Phase I/Ib oncology trials in China and Australia as well as NSP's Phase III inflammatory bowel disease ("IBD") trial on HMPL-004 in the United States. Spending during the period by Hutchison MediPharma Limited ("HMP") and its partners on these seven clinical programmes totalled $15.2 million (H1 2012: $6.9m).

· Cash and cash equivalents held in our Drug R&D Division JVs totalled $26.2 million (31 December 2012: nil).





Consumer Products Division

· Sales on continuing operations up 32% to $5.5 million (H1 2012: $4.2m).

· Net loss on continuing operations attributable to Chi-Med equity holders of $0.4 million (H1 2012: -$0.5m).

· Discontinuation of operations of Sen France and infant formula in China with total net loss attributable to Chi-Med equity holders of $1.4 million, of which $0.4 million is non-cash.

· Continuing expansion of the broad organic and natural product line of Hutchison Hain Organic Holdings Limited ("Hutchison Hain Organic").



Christian Hogg, CEO of Chi-Med, said:



"The new IFRS11 accounting standard means we can no longer consolidate the revenues of our JVs, and we therefore report a considerable reduction in Group consolidated revenues. However, the Divisional results show continued strong revenue growth, as does our Consolidated Group profit.



There has been much comment on whether economic growth in China is slowing, but it is quite clear this is not the case in the pharmaceutical sector, where the progressive widening and deepening of the State's National Healthcare Plan and the growth in personal incomes continue to drive strong growth. This is reflected in the results for our China Healthcare Division, which will also benefit in future from planned pricing and the easing of currently high raw material costs on one of our lead products. We also expect to benefit from the values of our JVs' land holdings which we expect to more than cover the costs of the planned relocation and expansion of the production facilities.



Our Drug R&D Division continues to make very impressive strides in its drug development programme and in partnership agreements with leading multinational pharmaceutical companies, all of which are adding substantial shareholder value and are set for continued major growth. Aggregate cash and equity injections and contractual obligations to HMP from these partnerships were $38.1 million compared to $0.6 million in the same period last year. Our partnerships are funding the seven clinical trials we now have under way, including Phase III trials of our lead drug candidate HMPL-004 in the US and the six Phase I trials of our other drug candidates, which are showing exciting promise. We look for further continued strong progress and for potential additional steps in partnership agreements.



Our Consumer Products Division is now focused on expanding its profitable growth categories with Hutchison Hain Organic by launching new products into the Hong Kong and mainland China market, as well as into selected other countries in Asia.



Overall, this has been another period of good progress, which further demonstrates the strength of our growth platform and its continued long-term potential. We expect profitable growth to continue for the second half of 2013 and beyond with further substantial creation of shareholder value."



Ends

IC VIEW

China's economy may be slowing, but spending on healthcare is not. Trading on a 15 per cent discount to analysts' 600p a share sum-of-the-parts valuations, the shares remain a buy.

A buy in this weeks IC- China's economy may be slowing, but spending on healthcare is not. Trading on 15% discount to analysts 600p a share sum of the parts valuation .

Back to its highs.

Director Deals - Hutchison China Meditech Ltd (HCM)

BFN

Christopher Nash, Non Executive Director, bought 8,506 shares in the company on the 7th August 2013 at a price of 584.00p. The Director now holds 26,506 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

Analyst briefing on Chi-Med's R&D business

RNS


RNS Number : 5607P

Hutchison China Meditech Limited

03 October 2013












Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)





Analyst briefing on Chi-Med's pharmaceutical R&D business on 9 October 2013





London: Thursday, 3 October 2013: Chi-Med today announces that it will host a briefing to update investors and analysts on Hutchison MediPharma ("HMP"), its majority owned pharmaceutical R&D division, in London on 9 October 2013.



Over the past several years, HMP has built an impressive pipeline of oral, small molecule cancer drugs and proprietary botanical drugs for inflammatory diseases. The briefing will focus on this pipeline.



HMP's current clinical pipeline includes: Fruquintinib, Sulfatinib, Epitinib, Theliatinib and Volitinib, each of which has the potential to treat a number of cancers, and HMPL-004, its lead candidate for ulcerative colitis and Crohn's disease.



In addition, HMP has formed key partnerships with major global pharmaceutical companies, including AstraZeneca and Nestlé Health Science.



The briefing will also cover HMP's pre-clinical research and the ongoing Phase III clinical development of HMPL-004, which is being undertaken by Nutrition Science Partners, a 50:50 joint venture between Chi-Med and Nestlé Health Science.



During the briefing, Dr Andrew Mortlock, Vice President of Cancer Research and Development Projects of AstraZeneca will give a presentation entitled, "Oncology in China".



Other key presenters at the briefing will be:



· Dr Weiguo Su, Ph.D. Chief Scientific Officer of HMP. Prior to joining HMP, Dr Su spent fifteen years with Pfizer's US R&D organisation where he was responsible for the delivery of several high quality new drug candidates into the clinic.



· Dr Hua Mu, Chief Medical Officer of HMP. Prior to joining HMP, Dr Mu worked at Roche, Biogen Idec, Abraxis and most recently, Genentech. During his career, he has been involved in the development of a number of successful oncology drugs including Xeloda ®, Abraxane ® and Avastin ®.



Mr Christian Hogg, Chief Executive Officer of Chi-Med, and Mr Johnny Cheng, Chief Financial Officer of Chi-Med, will also give presentations covering HMP's overall R&D strategy and its funding.



The briefing will take place at The Brewery (The James Watt room), 52 Chiswell Street, London, EC1Y 4SD on 9 October 2013 at 9:30 am, with registration starting from 9:15 am. Please contact Ms Janine Hagan by email at janine.hagan@citigatedr.co.uk for registration.



Ends

Lilly Deal for Fruquintinib

RNS


RNS Number : 0695Q

Hutchison China Meditech Limited

09 October 2013












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Cancer Therapy Collaboration with Lilly





London: Wednesday, 9 October 2013: Hutchison MediPharma Limited ("HMP"), an R&D company majority owned by Chi-Med, today announces that it has entered into a licensing, co-development, and commercialisation agreement in China with Eli Lilly and Company ("Lilly") for Fruquintinib (HMPL-013), a targeted oncology therapy for the potential treatment of various types of solid tumours. Fruquintinib, a selective inhibitor of the Vascular Endothelial Growth Factor ("VEGF") receptor tyrosine kinases, was discovered by HMP and is currently in Phase II testing in China.



Under the terms of the agreement, the costs of future development of Fruquintinib in China, to be carried out by HMP, will be shared between HMP and Lilly. HMP will potentially receive a series of payments of up to US$86.5 million, including upfront payments and development and regulatory approval milestones. Should Fruquintinib be successfully commercialised in China, HMP would receive tiered royalties starting in the mid-teens percentage of net sales. Additional terms of the agreement were not disclosed.



Christian Hogg, Chief Executive Officer of Chi-Med said: "Our belief is that Fruquintinib has potential activity against multiple tumour types with high incidence rates and may benefit patients with significant unmet medical needs in China. The collaboration with Lilly will allow for Fruquintinib to be developed across various tumour types in China and at a far greater speed than if we went alone."



"We are excited to collaborate with Hutchison MediPharma in the development of this potential new cancer therapy," said Jacques Tapiero, Lilly Senior Vice President and President of Emerging Markets. "In Lilly's emerging markets business, we are focused on providing patients with innovative medicines from our own pipeline and through collaborations with respected science-based companies such as HMP. Together, we are committed to help meet the medical needs of oncology patients in China."



Ends

Payment From Janssen Pharmaceuticals

RNS


RNS Number : 0697Q

Hutchison China Meditech Limited

09 October 2013


Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)


Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.



London: Wednesday, 9 October 2013: Chi-Med today announces that Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, is set to receive a milestone payment of US$6 million from Janssen Pharmaceuticals, Inc. ("Janssen"), pursuant to the global strategic alliance (the "Agreement") to develop novel small-molecule therapeutics against a target in the area of inflammation/immunology entered into by the companies in June 2010.

The US$6 million milestone was triggered by a compound, the Candidate, discovered by HMP in collaboration with Janssen meeting certain development candidate criteria pursuant to the Agreement. Upon achievement of specific clinical development and approval milestones, HMP may potentially receive up to an additional US$90.5 million and is entitled to royalties on worldwide sales upon commercialisation of a product by Janssen.



Ends

Director/PDMR Shareholding

RNS


RNS Number : 6600Q

Hutchison China Meditech Limited

16 October 2013












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Director's Shareholding





London: Wednesday, 16 October 2013: Chi-Med received notification on 16 October 2013 that Ms Edith Shih, Non-executive Director and Company Secretary of Chi-Med, purchased 20,000 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP6.20 each on 15 October 2013.



Following this purchase, Ms Shih is beneficially interested in 20,000 Shares, representing approximately 0.04% of the current issued share capital of Chi-Med.





Ends